Coherus Biosciences Inc (CHRS) : Vhcp Management Ii reduced its stake in Coherus Biosciences Inc by 50.0% during the most recent quarter end. The investment management company now holds a total of 129,629 shares of Coherus Biosciences Inc which is valued at $3,636,093 after selling 129,630 shares in Coherus Biosciences Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Coherus Biosciences Inc makes up approximately 1.53% of Vhcp Management Ii’s portfolio.
Other Hedge Funds, Including , Kennedy Capital Management added CHRS to its portfolio by purchasing 54,829 company shares during the most recent quarter which is valued at $1,537,953. Coherus Biosciences Inc makes up approx 0.03% of Kennedy Capital Management’s portfolio.California State Teachers Retirement System boosted its stake in CHRS in the latest quarter, The investment management firm added 600 additional shares and now holds a total of 62,440 shares of Coherus Biosciences Inc which is valued at $1,692,124. Tower Research Capital (trc) sold out all of its stake in CHRS during the most recent quarter. The investment firm sold 400 shares of CHRS which is valued $10,240.Nationwide Fund Advisors boosted its stake in CHRS in the latest quarter, The investment management firm added 21,713 additional shares and now holds a total of 36,445 shares of Coherus Biosciences Inc which is valued at $1,084,603.
Coherus Biosciences Inc opened for trading at $28.15 and hit $28.5982 on the upside on Monday, eventually ending the session at $28.25, with a gain of 0.89% or 0.25 points. The heightened volatility saw the trading volume jump to 3,01,154 shares. Company has a market cap of $1,233 M.
Many Wall Street Analysts have commented on Coherus Biosciences Inc. Robert W. Baird Initiated Coherus Biosciences Inc on Oct 19, 2016 to “Outperform”, Price Target of the shares are set at $40.Maxim Group Initiated Coherus Biosciences Inc on Sep 7, 2016 to “Buy”, Price Target of the shares are set at $43.
Coherus BioSciences Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company’s clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF) and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company’s product pipeline includes anti-TNF product candidate CHS-0214 an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials and anti-TNF product candidate CHS-1420 an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate CHS-1701 a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.